Search 

Eudendron is an Italian biotech company founded by Dr. Mauro Angiolini and Dr. Fabio Zuccotto. Eudendron develops anti-cancer agents for applications within the precision medicine model, adopting a tumor agnostic approach and targeting populations of patients hosting genetically defined cancers. Purpose of the company is to advance novel cancer treatments from their inception to Phase I/II. The activities of the company are also focused on the identification of novel drugs effective against protein kinase mutations responsible for clinical drug resistance. Eudendron discovered and patented a new class of highly specific inhibitors with excellent anti-cancer properties against several types of cancer cells. Patents in Europe and in USA have already been granted covering inhibitors of relevant oncology targets and their mutations. Lung and thyroid cancer, lymphoma, neuroblastoma and cutaneous cancer are diseases with unmet medical need of particular interest. Especially for neuroblastoma, the company identified drugs with a potent and specific profile. Eudendron is committed to identify Investors and/or industrial Partners to advance the pipeline programs toward the clinical stage. Basket trials will be finally designed following an agnostic clinical development.

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in 2021. Additional products are in encapsulation feasibility studies including targeting dry eye disease and other solid tumors. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. The key platform patent was awarded by USPTO in 2019. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 18 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

Partnership between Ministry of Foreign Affair and Ministry of Higher Education and Science of Denmark. Help danish high-tech companies and research instututes to enter Chinese market and find Chinese collaborators

总部加拿大温哥华的VC机构，负责把海外投资的项目引进国内商业化落地

荷兰驻华大使馆。
协助荷兰企业对接中国合作伙伴。